Milestone Pharmaceuticals Inc. Logo

Milestone Pharmaceuticals Inc.

Developing a self-administered nasal spray for at-home treatment of acute cardiac events.

MIST | US

Overview

Corporate Details

ISIN(s):
USU6005B1045 (+1 more)
LEI:
549300P43IPGW3Q3Y026
Country:
United States of America
Address:
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, 07039 MONTREAL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for episodic cardiovascular conditions. The company's lead investigational product is etripamil, a proprietary, novel calcium channel blocker delivered as a self-administered nasal spray. This therapy is designed for the rapid termination of paroxysmal supraventricular tachycardia (PSVT) episodes in an at-home setting, addressing a significant unmet need for treatment outside of the emergency department. Milestone is also exploring etripamil's potential for other conditions, such as atrial fibrillation with rapid ventricular rate (AFib-RVR), to provide patients with control over acute cardiac events.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Milestone Pharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Milestone Pharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Milestone Pharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea
007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea
293780
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden
APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea
291650
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America
APVO
Aptorum Group Ltd Logo
Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Develops oral film drugs for CNS disorders and severe allergies.
United States of America
AQST
Arbutus Biopharma Corp Logo
A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).
United States of America
ABUS
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway
ABS

Talk to a Data Expert

Have a question? We'll get back to you promptly.